American Journal of Obstetrics & Gynecology
Volume 197, Issue 3, Supplement , Pages S90-S95 , September 2007

Toward elimination of perinatal human immunodeficiency virus transmission in the United States: effectiveness of funded prevention programs, 1999-2001

A subset of this analysis was presented in preliminary form at the 2005 HIV Prevention Conference, Atlanta, Georgia, June 14, 2005.

  • Stephanie L. Sansom, PhD, MPP, MPH

      Affiliations

    • Division of HIV/AIDS Prevention, National Center for HIV, STD, and TB Prevention, Information Technology Support, Centers for Disease Control and Prevention, Atlanta, GA
    • Corresponding Author InformationReprints: Stephanie L. Sansom, PhD, MPP, MPH, HIV/AIDS Prevention, National Center for HIV, STD, and TB Prevention, Centers for Disease Control and Prevention, MS E-48, 1600 Clifton Rd, Atlanta, GA 30333
    • ,
  • Norma S. Harris, PhD, MSPH

      Affiliations

    • Division of HIV/AIDS Prevention, National Center for HIV, STD, and TB Prevention, Information Technology Support, Centers for Disease Control and Prevention, Atlanta, GA
    • ,
  • Ramses Sadek, PhD

      Affiliations

    • Division of HIV/AIDS Prevention, National Center for HIV, STD, and TB Prevention, Information Technology Support, Centers for Disease Control and Prevention, Atlanta, GA
    • ,
  • Margaret A. Lampe, RN, MPH

      Affiliations

    • Division of HIV/AIDS Prevention, National Center for HIV, STD, and TB Prevention, Information Technology Support, Centers for Disease Control and Prevention, Atlanta, GA
    • ,
  • Nan M. Ruffo

      Affiliations

    • Division of HIV/AIDS Prevention, National Center for HIV, STD, and TB Prevention, Information Technology Support, Centers for Disease Control and Prevention, Atlanta, GA
    • Northrop Grumman Information Technology, Information Technology Support, Centers for Disease Control and Prevention, Atlanta, GA.
    • ,
  • Mary Glenn Fowler, MD, MPH

      Affiliations

    • Division of HIV/AIDS Prevention, National Center for HIV, STD, and TB Prevention, Information Technology Support, Centers for Disease Control and Prevention, Atlanta, GA

Received 15 December 2006 ,Revised 14 February 2007 ,Accepted 1 March 2007.

References 

  1. CDC. Reduction in perinatal transmission of human immunodeficiency virus—United States, 1985-2006. MMWR Morbid Mortal Wkly Rep. 2006;21:592–597
  2. Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment (Pediatric AIDS Clinical Trials Group Protocol 076 Study Group). N Engl J Med. 1994;331:1173–1180
  3. Cooper ER, Charurat M, Mofenson L, et al. Combination antiretroviral strategies for the treatment of pregnant HIV-1-infected women and prevention of perinatal HIV-1 transmission. J Acquir Immune Defic Syndr. 2002;29:484–494
  4. U.S. Public Health Service Task Force. Recommendations for use of antiretroviral drugs in pregnant HIV-1 infected women for maternal health and interventions to reduce perinatal HIV-1 transmission in the United States. 2005;Nov 17. Available at: http://aidsinfo.nih.gov/Guidelines/GuidelineDetail.aspx?MenuItem=Guidelines&Search=Off&GuidelineID=9&ClassID=2. Accessed March 31, 2006.
  5. Wade NA, Birkhead GS, Warren BL, et al. Abbreviated regimens of zidovudine prophylaxis and perinatal transmission of the human immunodeficiency virus. N Engl J Med. 1998;339:1409–1414
  6. Guay LA, Musoke P, Hom DL, et al. Phase I/II trial of HIV-1 hyperimmune globulin for the prevention of HIV-1 vertical transmission in Uganda. AIDS. 2002;16:1391–1400
  7. PETRA Study Team. Efficacy of three short-course regimens of zidovudine and lamivudine in preventing early and late transmission of HIV-1 from mother to child in Tanzania, South Africa, and Uganda (Petra study): a randomised, double-blind, placebo-controlled trial. Lancet. 2002;359:1178–1186
  8. Moodley D, Moodley J, Coovadia H, et al. A multicenter randomized controlled trial of nevirapine versus a combination of zidovudine and lamivudine to reduce intrapartum and early postpartum mother-to-child transmission of human immunodeficiency virus type 1. J Infect Dis. 2002;187:725–735
  9. Davis S, Byers R, Lindegren ML, Caldwell MB, Karon JM, Gwinn M. Prevalence and incidence of vertically acquired HIV infection in the United States. JAMA. 1995;274:952–955
  10. Centers for Disease Control and Prevention. Characteristics of persons living with AIDS at the end of 1997. HIV/AIDS Surveillance Supplemental Report 1990;5:1-14. Available at: http://www.cdc.gov/hiv/stats/hasrsupp51.pdf. Accessed March 31, 2006. 11. Centers for Disease Control and Prevention. HIV prevention strategic plan through 2005. 2001; Atlanta, GA: Author. Available at: http://www.cdc.gov/hiv/partners/psp.htm. Accessed March 31, 2006.
  11. Centers for Disease Control and Prevention. HIV preventtion strategic plan through 2005. Atlanta, GA: Author; 2001;Avilable at: http://www.cdc.gov/hiv/partners/psp/htm. accessed March 31, 2006.
  12. Holtgrave DR, Gilliam A, Gentry D, Sy FS. Evaluating HIV prevention efforts to reduce new infections and ensure accountability. AIDS Educ Prev. 2002;14(Suppl A):1–4
  13. Rugg D, Buehler J, Renaud M, et al. Evaluating HIV prevention: a framework for national, state and local levels. Am J Eval. 1999;20:35–56
  14. Centers for Disease Control and Prevention. Guidelines for national human immunodeficiency virus case surveillance, including monitoring for human immunodeficiency virus infection and acquired immunodeficiency syndrome. MMWR Morb Mortal Wkly Rep. 1999;48(RR-13):1–28Available at: http://www.cdc.gov/mmwr/preview/mmwrhtml/rr4813a1.htm. Accessed March 31, 2006.
  15. In:  Holtgrave DR editors. Handbook of economic evaluation of HIV prevention programs. New York (NY): Plenum; 1998;
  16. Sansom S, Anderson J, Farnham PG, Dominguez K, Soorapanth S, Clark J. Updated estimates of health care utilization and costs among perinatally HIV-infected children. J Acquir Immune Defic Syndr. 2006;41:521–526
  17. Sansom S, Anderson J, Dominguez K, Earp MJ, Farnham P. Updated quality adjusted life year estimates for perinatally HIV-infected children. In: Presented at the 27th Annual Meeting of the Society for Medical Decisonmaking, Oct 24, San Francisco, CA.. 2005;
  18. Tengs TO, Adams ME, Pliskin JS, et al. Five-hundred life-saving interventions and their cost-effectiveness. Risk Anal. 1995;15:369–390
  19. Martin J, Hamilton B, Ventura S, Menacher F, Park MM, Sutton PD. Births: final data for 2001. Natl Vital Stat Rep. 2002;51:Available at: http://www.cdc.gov/nchs/data/nvsr/nvsr51/nvsr51_02.pdf. Accessed March 31, 2006.
  20. Garcia P, Kalish L, Pitt J, et al. Maternal levels of plasma human immunodeficiency virus type 1 RNA and the risk of perinatal transmission. N Engl J Med. 1999;341:394–402
  21. Welles S, Pitt J, Colgrave R, et al. HIV-1 genotypic zidovudine drug resistance and the risk of maternal-infant transmission in the Women and Infant Study Transmission Group. AIDS. 2000;14:263–271
  22. Dunn DT, Newell ML, Ades AE, Peckham CS. Risk of human immunodeficiency virus type 1 transmission through breastfeeding. Lancet. 1992;340:585–588
  23. The International Perinatal HIV Group. The mode of delivery and risk of vertical transmission of human immunodeficiency virus type-1: a meta-analysis of 15 prospective cohort studies. N Engl J Med. 1999;340:977–987

 The findings and views expressed herein are those of the authors and do not necessarily represent the views of the Centers for Disease Control and Prevention.

PII: S0002-9378(07)00295-5

doi: 10.1016/j.ajog.2007.03.005

American Journal of Obstetrics & Gynecology
Volume 197, Issue 3, Supplement , Pages S90-S95 , September 2007

Article Tools

* Image Usage & Resolution